Latest News for: radm

Edit

Great Power Competition - Special Operations - RADM Gary Rosholt

Rumble 10 Dec 2025
Click the Rumble article link to see the video ....
Edit

2025 Society for NeuroOncology Annual MeetingThe Tetravalent Death Receptor 5 Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results From the Randomized, Registrational, Phase 2 ChonDRAgon Study 21st Annual Industry/Academia Precision Oncology & Radmed Symposium (SNO 2025 INBRX-109 GBM Preclinical DataCTOS 2025 ChonDRAgon Primary Data Abstract Nov25Inhibrx 21st Annual Precision Oncology DR5 Agonist Clinical Data Nov25) (Inhibrx Biosciences Inc)

Public Technologies 22 Nov 2025
). ‌BACKGROUND. GBM tumor cell lines have variable in vitro sensitivities to ozekibart and TMZ as single agents but typically exhibit enhanced sensitivity to combination treatment ... A B. Treatment. p value. * ozekibart vs vehicle. 0.001 ... 0.02 ... 0.003 ... 0.02 ... 0.04.
Edit

The Tetravalent Death Receptor 5 Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results From the Randomized, Registrational, Phase 2 ChonDRAgon Study 21st Annual Industry/Academia Precision Oncology & Radmed Symposium (CTOS 2025 ChonDRAgon Primary Data Abstract Nov25Inhibrx 21st Annual Precision Oncology DR5 Agonist Clinical Data Nov25) (Inhibrx Biosciences Inc)

Public Technologies 14 Nov 2025
) CTOS 2025. Boca Raton, FL, USA; 12-15 November 2025. THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN CONVENTIONAL CHONDROSARCOMA. RESULTS FROM THE RANDOMIZED, REGISTRATIONAL, PHASE 2 CHONDRAGON STUDY. Objective ... Methods ... ≥65 years ... R.L.
Edit

The Tetravalent Death Receptor 5 Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results From the Randomized, Registrational, Phase 2 ChonDRAgon Study 21st Annual Industry/Academia Precision Oncology & Radmed Symposium (CTOS2025 ChonDRAgon Oral FINAL Version) (Inhibrx Biosciences Inc)

Public Technologies 14 Nov 2025
). The Tetravalent Death Receptor 5 Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma. Results From the Randomized, Registrational, Phase 2 ChonDRAgon Study. Robin L ... Wilky,6 Jean-Yves Blay,7 Peter Reichardt,8 Javier Martín-Broto,9 Dale R ... de.
  • 1

Article Search

tools
×
×
×
×